comparemela.com

Latest Breaking News On - Exome aggregation consortium - Page 1 : comparemela.com

Frontiers | A Novel Probable Pathogenic PSEN2 Mutation p Phe369Ser Associated With Early-Onset Alzheimer s Disease in a Chinese Han Family: A Case Report

Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China The pathogenesis of Alzheimer s disease is complex, and early-onset Alzheimer s disease (EOAD) is mostly influenced by genetic factors. Presenilin-1, presenilin-2 (PSEN2), and amyloid precursor protein are currently known as the three main causative genes for autosomal dominant EOAD, with the PSEN2 mutation being the rarest. In this study, we reported a 56-year-old Chinese Han proband who presented with prominent progressive amnesia, aphasia, executive function impairment, and depression 5 years ago. The 3-year follow-up showed that the patient experienced progressive brain atrophy displayed on magnetic resonance imaging (MRI) and dramatic cognitive decline assessed by neuropsychological evaluation. This patient was clinically diagnosed as EOAD based on established criteria. A heterozygous variant (NM 000447.2: c.1106T>C) of PSEN2 was identified for the first time in this patient and her

H3Africa Consortium Primes A Continent For Large-Scale Genomics Research

February 2, 2021 By Deborah Borfitz February 2, 2021 | The Human Heredity and Health in Africa (H3Africa) Consortium is endeavoring to foster collaborative research on the world’s second-most populous continent, having spent the past decade bolstering the genomics research capacity here with 48 projects across 34 countries. Clinical geneticist and physician-scientist Neil Hanchard, M.D., Ph.D., through his academic position at Baylor College of Medicine, has, for example, been involved in a H3Africa-sponsored genomic study in children coinfected with HIV and tuberculosis whose principal investigator is based in Botswana. Most recently, Hanchard was one of the senior authors on an H3Africa-sponsored study published in

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.